Alcohol Drinkers Exposure to preventive Therapy for Tuberculosis
The ADEPT study is a one arm trial of INH preventive therapy among HIV positive adults with latent TB at ISS Clinic (n=300).
Aim 1: To examine the safety and tolerability of TB preventive therapy for HIV-infected drinkers (6 months of isoniazid -INH), measured by hepatotoxicity and treatment discontinuation rates overall and by level of drinking.
Aim 2: To compare the level of TB preventive therapy adherence by level of drinking.
Aim 3: To determine whether the benefits of providing TB preventive therapy to HIV-infected drinkers in resource-limited settings outweigh the risks compared to no treatment.
Principal Investigators: Dr. Judith Hahn (UCSF) and Dr. Winnie Muyindike (MUST)